Corpus Intelligence IC Memo — INLAND HOSPITAL 2026-04-26 06:16 UTC
IC Memo — INLAND HOSPITAL
Investment Committee Memorandum | ME | 33 beds | Grade C | EBITDA uplift $4.7M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

INLAND HOSPITAL

CCN 200041 | KENNEBEC, ME | 33 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

INLAND HOSPITAL is a 33-bed under-performing / distressed in KENNEBEC, ME with $63.3M in net patient revenue and a -32.8% operating margin. The hospital serves a payer mix of 25.8% Medicare, 13.0% Medicaid, and 61.2% commercial.

Thesis: Turnaround. Our ML models identify $4.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -32.8% to -25.4% (+736bps).

Net Revenue HCRIS$63.3M
Current EBITDA COMPUTED$-20.8M
Operating Margin COMPUTED-32.8%
Occupancy HCRIS48.2%
Revenue / Bed COMPUTED$1.9M
Net-to-Gross HCRIS40.7%
Distress Probability ML50.6%

2. Market Context & Competitive Position

38
ME Hospitals
-8.3%
State Median Margin
23
Comparable Hospitals

ME has 38 Medicare-certified hospitals with a median operating margin of -8.3%. The target's margin of -32.8% places it below the state median. Among 23 size-comparable peers (16-66 beds), the median margin is -5.2%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (16-66), prioritizing same-state peers. 23 hospitals in the comp set.

HospitalStateBedsRevenueMargin
INLAND HOSPITAL (Target)ME33$63.3M-32.8%
YORK HOSPITALME54$197.1M-3.6%
REDINGTON-FAIRVIEW GENERAL HOSME25$135.4M-3.6%
THE AROOSTOOK MEDICAL CENTERME34$134.8M-23.5%
LINCOLNHEALTHME25$116.8M-0.9%
WALDO COUNTY GENERAL HOSPITALME25$115.4M-6.4%
FRANKLIN MEMORIAL HOSPITALME46$103.4M-17.3%
STEPHENS MEMORIAL HOSPITAL - CME25$100.5M4.2%
MAINE COAST MEMORIAL HOSPITALME45$98.0M-5.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $4.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.3M+210bp18mo
Cost to Collect4.5%2.5%$1.3M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.3M+198bp12mo
A/R Days Reduction5200.0%3800.0%$771K+122bp9mo
Clean Claim Rate88.0%96.0%$41K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.3M
Cost to Collect
$1.3M
Denial Rate Reduction
$1.3M
A/R Days Reduction
$771K
Clean Claim Rate
$41K
Total EBITDA Uplift$4.7M
Current EBITDA$-20.8M
+ RCM Uplift+$4.7M
Pro Forma EBITDA$-16.1M
Current Margin-32.8%
Pro Forma Margin-25.4%
WC Released (1x)$2.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-32.0M$-90.4M0.00x-100.0%
Base (11x exit)10.0x11.0x$-32.0M$-109.9M0.00x-100.0%
Bull Case9.0x11.0x$-28.8M$-104.9M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-28.8M$-122.9M0.00x-100.0%
Bear Case11.0x10.0x$-35.2M$-103.4M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-35.2M$-125.1M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 50.6% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 23 hospitals with 16-66 beds
  • Same-state prioritization (n=24)
  • Comp margins: P25=-9.8% / P50=-5.2% / P75=0.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.